Losartan treatment significantly attenuates the fibrotic changes in the corpus cavernosum of castrated rats.


Journal

Revista internacional de andrologia
ISSN: 1698-0409
Titre abrégé: Rev Int Androl
Pays: Spain
ID NLM: 101500934

Informations de publication

Date de publication:
Historique:
received: 16 01 2018
revised: 22 06 2018
accepted: 25 07 2018
pubmed: 25 9 2018
medline: 1 10 2021
entrez: 25 9 2018
Statut: ppublish

Résumé

The aim of this study is to evaluate the effects of castration and subsequent losartan administration on the fibrosis-related parameters in the corpora cavernosa of castrated rats. Twenty-four male rats were divided into four equal groups. Group 1:sham surgery plus vehicle (0.9% NaCl) (control:con), group 2:sham surgery plus losartan (con+los), group 3: castration plus vehicle (castration:cast) and group 4:castration plus losartan (cast+los). After four weeks of oral losartan treatment, corporal levels of transforming growth factor-beta (TGF-β), thrombospondin-1 (TSP-1), alpha-actin, beta-actin and fibronectin were investigated by ELISA kits. Changes in the collagen and smooth muscle content were evaluated by histological analysis with Masson trichrome staining. Initial and post-treatment body weights of rats were similar among groups. Castration significantly increased the expression of TGF-β, TSP-1 and fibronectin and resulted in a significant decrease in alpha-actin levels in the corpora cavernosa. Administration of losartan reduced the levels of TGF-β, TSP-1 and fibronectin in castrated rats. Alpha actin levels also increased after losartan treatment. Beta-actin levels were not significantly different among 4 groups. The levels of all markers were similar in group 1 and 2. Rate of fibrosis was significantly higher in castrated rats and treatment with losartan reduced this rate. Castration increased the expression of fibrosis-related markers in the corpora cavernosa of rats. Administration of losartan significantly attenuated those changes and exerted an antifibrotic effect.

Identifiants

pubmed: 30245178
pii: S1698-031X(18)30057-8
doi: 10.1016/j.androl.2018.07.001
pii:
doi:

Substances chimiques

Actins 0
Angiotensin II Type 1 Receptor Blockers 0
Biomarkers 0
Fibronectins 0
Thrombospondin 1 0
Transforming Growth Factor beta 0
thrombospondin 1, rat 0
Testosterone 3XMK78S47O
Collagen 9007-34-5
Losartan JMS50MPO89

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

14-20

Informations de copyright

Copyright © 2018. Publicado por Elsevier España, S.L.U.

Auteurs

Faruk Kucukdurmaz (F)

Sutcu Imam University, Department of Urology, Kahramanmaras, Turkey. Electronic address: farukfkd@yahoo.com.

Erkan Efe (E)

Sutcu Imam University, Department of Urology, Kahramanmaras, Turkey.

Ergul Belge Kurutas (EB)

Sutcu Imam University, Department of Biochemistry, Kahramanmaras, Turkey.

Caner Olmez (C)

Sutcu Imam University, Department of Urology, Kahramanmaras, Turkey.

Mithat Temizer (M)

Gaziantep Community Health Center, Gaziantep, Turkey.

Sefa Resim (S)

Sutcu Imam University, Department of Urology, Kahramanmaras, Turkey.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH